With advances in treatment and screening for earlier detection, oncologists have improved cancer survival rates dramatically. That is excellent news, but the surging number of survivors means it is increasingly important for providers to focus more diligently on what patients need to thrive after treatment. To access this subscriber-only content please log in or subscribe.If […]
Speaking at an FDA Roundtable on Cell and Gene Therapy, FDA Commissioner Marty Makary questioned the construct of “levels of evidence” as artificial and dogmatic,…
Booth 10025 became an unlikely crowd magnet at the exhibit hall at the annual meeting of the American Society of Clinical Oncology that ended earlier…
For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had…
Harmon Eyre, MD, died on May 31 in Salt Lake City. He was 84 years old. From 1993 to 2008, he served as the chief…
Our Hispanic community is a vibrant and essential part of the American tapestry, contributing richly to the country’s society, culture, and economy. Yet, when it…
In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual…
Experts discuss how the latest data in prostate, gastric, breast & ovarian cancers and oncogene-addicted NSCLC could impact clinical practice
Researchers from the University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with…
Uday Popat, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the results of a Phase I/II study (NCT03247088) investigating a myeloablative…
At the end of her first day on the job as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer…
